Ritlecitinib in clinical practice: a real-world study of efficacy, safety and prior Janus kinase inhibitor impact in alopecia areata
Ritlecitinib 50 mg daily showed promising efficacy and acceptable safety in Chinese patients with moderate-to-severe alopecia areata, regardless of previous Janus kinase inhibitor therapy.
Authors
- Sean L. Zheng (ORCID: https://orcid.org/0000-0002-5762-6392)
- Ru Dai (ORCID: https://orcid.org/0000-0002-2691-8544)
- Luming Duan (ORCID: https://orcid.org/0000-0001-6675-9413)
- Xianjie Wu (ORCID: https://orcid.org/0000-0002-5604-5801)
- Siqi Li (ORCID: https://orcid.org/0000-0003-4026-963X)
Institutions
- Second Affiliated Hospital of Zhejiang University (CN)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2025-05-04
- DOI
- https://doi.org/10.1093/ced/llaf194
- Citations
- 2
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.94